# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce P-TEFb and its role in transcriptional elongation
- describe limitations of current P-TEFb assays

## SUMMARY OF THE INVENTION

- introduce novel assay for visualizing P-TEFb by fluorescence complementation

## DETAILED DESCRIPTION OF THE INVENTION

- describe basic operation of the invention
- introduce P-TEFb construct and P-TEFb target construct
- describe signal pairs and their use in the invention
- introduce bimolecular fluorescence complementation assay (BiFC)
- describe fluorophore fragments and their use in BiFC
- introduce FRET pair as alternative signal pair
- describe polypeptide constructs of the invention
- introduce P-TEFb polypeptide construct
- describe P-TEFb moiety and its requirements
- introduce Cdk9 and CycT1 subunits of P-TEFb
- describe nuclear localization signal in P-TEFb construct
- introduce fluorophore fragment in P-TEFb construct
- describe linker sequence in P-TEFb construct
- introduce P-TEFb target polypeptide construct
- describe P-TEFb target moiety and its requirements
- introduce C-terminal domain of RNA polymerase II as P-TEFb target moiety
- describe nuclear localization sequence in P-TEFb target construct
- introduce linker sequence in P-TEFb target construct
- describe accessory features of the constructs
- introduce antibody epitope as accessory feature
- describe gene constructs of the invention
- introduce nucleic acid sequences encoding polypeptide constructs
- describe promoters and regulatory elements in nucleic acid sequences
- introduce transformation of target cells
- describe transient and stable transformation methods
- introduce cell or whole organism expressing P-TEFb and P-TEFb target constructs
- describe P-TEFb assays of the invention
- introduce stimulus and its effect on P-TEFb activity
- describe measurement of signal in P-TEFb assays
- introduce FACS process for quantifying cells with reconstituted signal moiety
- describe detection of signal at varying time intervals
- introduce use of the system in various contexts
- describe method of assessing treatment's effect on P-TEFb activity
- introduce screening protocol for P-TEFb modulator agents
- describe importance of P-TEFb activity in cancer and inflammation
- introduce personalized medicine applications

## EXAMPLES

### Demonstration of the P-TEFb Assay in Cultured Cells

- construct YN.CTD and YC.PTEFb chimeras
- express proteins in cells
- confirm protein expression by Western blot
- demonstrate P-TEFb release from 7SK snRNP
- detect interactions between P-TEFb and RNA polymerase II CTD
- monitor P-TEFb activation by BiFC in cells
- observe time-dependent increase in BiFC signals
- test P-TEFb-releasing agents
- examine YC fused with CDK9 or CycT1
- optimize plasmid ratios for BiFC signals

### Demonstration of the P-TEFb Assay Employing Venus Fluorescent Protein in HIV-1 Post-Integration Latency Model Cell Lines

- describe HIV-1 post-integration latency model cell lines
- test PKC agonists and P-TEFb-releasing agents as latency-reversing agents
- demonstrate synergistic activation of HIV-1 expression
- use BiFC assay to study P-TEFb activation
- show combined latency-reversing agent treatments lead to higher P-TEFb activations

